Delving into the Latest Updates on AD-70 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

ADM OXD, ADM-OXD, DOX OXD

+ [4]

Target-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Hematologic NeoplasmsNeoplasms

Originator Organization

Mitsubishi Tanabe Pharma Corp.

Active Organization-

Inactive Organization

Mitsubishi Tanabe Pharma Corp.Mitsubishi Pharma Corp.

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

The purpose of the study is to determine efficacy and safety of combination therapy with adjusted-dose docetaxel-oxaliplatin-capecitabine in patients with advanced gastric adenocarcinoma and intermediate general status.(defined as ECOG 2 or weight loss 10-25% or older that 70 years and no comorbidities nor functional dependency nor geriatric syndrome)

Start Date01 Nov 2008

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

[+1]

100 Clinical Results associated with AD-70

Login to view more data

100 Translational Medicine associated with AD-70

Login to view more data

100 Patents (Medical) associated with AD-70

Login to view more data

118

Literatures (Medical) associated with AD-70

01 Jan 2024·Journal of Colloid and Interface Science

The pH-dependent multiple nanozyme activities of copper-cerium dioxide and its application in regulating intracellular oxygen and hydrogen peroxide levels

Article

Author: Liu, Meiling ; Gong, Lin ; Zhang, Youyu ; Yao, Shouzhuo ; Fan, You ; Zhu, Yu ; Liu, Jing ; Zhu, Xiaohua

Cu doped CeO₂ (Cu-CeO₂) nanoparticles were synthesized via the hydrothermal method, exhibiting multiple nanozyme activities such as good oxidase-like (OXD), peroxidase-like (POD) and catalase-like (CAT) activities. These Cu-CeO₂ nanoparticles were successfully utilized to modulate the levels of oxygen and hydrogen peroxide in cells. The OXD and POD mimics showed optimal at pH of 3.5 and 4.0, but their activities significantly decreased under neutral or slightly acidic conditions. On the other hand, the CAT activity was excellent at pH 6.5, while the OXD and POD mimics were less effective. These findings demonstrated that nanozyme activity of Cu-CeO₂ nanoparticles is pH-dependent. Consequently, within the microenvironment of tumor cells, the CAT can efficiently catalyze the conversion of H₂O₂ into O₂, unaffected by H₂O₂/O₂ consuming mimics. Both oxygen indicator and oxygen tester measurements confirmed a significant increase in O₂ levels in phosphate-buffered saline (PBS). Furthermore, confocal microscopic imagings using fluorescence probes for H₂O₂ and O₂ validated the variations of H₂O₂/O₂ in cells. This study highlights the ability of Cu-CeO₂ to regulate intracellular reactive oxygen levels and its tremendous potential in nanotherapy and alleviating tumor hypoxia.

15 Feb 2023·Bioconjugate Chemistry

Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic–DEVD–Doxorubicin Conjugate for Targeted Cancer Therapy

Article

Author: Lee, Seokwoo ; Lee, Dong-Nyeong ; Lee, Young-Ho ; Park, Jooho ; Lee, Jun-Hyuck ; Yang, Seong-Bin ; Seo, Minho ; Shin, Dong Wook

In the development of new drugs, typical polymer- or macromolecule-based nanocarriers suffer from manufacturing process complexity, unwanted systematic toxicity, and low loading capacity. However, carrier-free nanomedicines have made outstanding progress in drug delivery and pharmacokinetics, demonstrating most of the advantages associated with nanoparticles when applied in targeted anticancer therapy. Here, to overcome the problems of nanocarriers and conventional cytotoxic drugs, we developed a novel, carrier-free, self-assembled prodrug consisting of a hydrophobic palmitic (16-carbon chain n-hexadecane chain) moiety and hydrophilic group (or moiety) which is included in a caspase-3-specific cleavable peptide (Asp-Glu-Val-Asp, DEVD) and a cytotoxic drug (doxorubicin, DOX). The amphiphilic conjugate, the palmitic-DEVD-DOX, has the ability to self-assemble into nanoparticles in saline without the need for any carriers or nanoformulations. Additionally, the inclusion of doxorubicin is in its prodrug form and the apoptosis-specific DEVD peptide lead to the reduced side effects of doxorubicin in normal tissue. Furthermore, the carrier-free palmitic-DEVD-DOX nanoparticles could passively accumulate in the tumor tissues of tumor-bearing mice due to an enhanced permeation and retention (EPR) effect. As a result, the palmitic-DEVD-DOX conjugate showed an enhanced therapeutic effect compared with the unmodified DEVD-DOX conjugate. Therefore, this carrier-free palmitic-DEVD-DOX prodrug has great therapeutic potential to treat solid tumors, overcoming the problems of conventional chemotherapy and nanoparticles.

01 Feb 2019·Materials Science and Engineering: CQ2 · ENGINEERING & TECHNOLOGY

Apoferritin nanocages with Au nanoshell coating as drug carrier for multistimuli-responsive drug release

Q2 · ENGINEERING & TECHNOLOGY

Article

Author: Chen, Yanwei ; Wu, Dan ; Liu, Yichun ; Shan, Guiye ; Li, Man

Cancer is one of the major causes of mortality worldwide. Therefore, it is necessary to provide an effective method of tumor therapy. Herein, we designed a new type of composite particle, apoferritin (APO) encapsulated doxorubicin (DOX), and the surface of APO was modified with Au nanoshell. As a nanocarrier, APO can carry chemotherapy drug DOX (APODOX) and release drug under acidic and high temperature conditions to reduce side effects of anticancer drugs. After covering Au nanoshell (APODOX-Au), the photothermal effect can be produced because of the unique surface plasmon resonance properties of gold nanoshell. This nanoplatform also provides the multi-stimuli responsive drug release system, which can achieve drug release in different conditions and have great potential in biomedical applications. Our investigation has demonstrated that APODOX-Au has good stability, high dispersibility and biocompatibility in vitro. The strong near-infrared absorption and good photothermal effect make sure the quick response to environmental changes (pH, temperature) to achieve drug release. These findings indicate that these nanoparticles have a potential application value in cancer treatment.

100 Deals associated with AD-70

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 1	-	Mitsubishi Tanabe Pharma Corp.	-
Neoplasms	Phase 1	JP	Mitsubishi Pharma Corp.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2021	Not Applicable	Renal Cell Carcinoma	16	Gemcitabine plus doxorubicin (Gem + Dox)	gjbpvkbaug(utodguiyvr) = no grade ≥ 2 reported events of cardiotoxicity lsclaubexj (erlufceypk ) View more	-	02 Mar 2021
ASCO_GI2020	Not Applicable	Adenocarcinoma	28	Perioperative DOX	(vzrgfiiqsr) = sjptpltyoh dpsicjmlle (khuwqntobh )	Positive	04 Feb 2020
AACR2015	Not Applicable	Breast Cancer	-	DOX-lipid conjugate	twwzrxtjfe(wzitkarewr) = llgogzztep bowvtaviui (hpilpzsnbc )	-	01 Aug 2015
ASCO2015	Not Applicable	Osteosarcoma	26	CP and DOX	(ctlwyrqhlo) = iewfzevtvl wxnggahyck (woinamxxcm ) View more	-	20 May 2015
ASCO2015	Not Applicable	Osteosarcoma	26	CP, DOX, and HDM	(ctlwyrqhlo) = pfrtubphvm wxnggahyck (woinamxxcm ) View more	-	20 May 2015
ASCO2015	Not Applicable	Sarcoma First line	41	Metastatic STS patients receiving single agent dox.	zozaepcxqr(rfgxesvbmy) = juruxyqukl cqtiglxbxq (bviznrtzhc )	-	20 May 2015
ASCO2005	Phase 2/3	Hepatocellular Carcinoma	339	T138067 250 mg/m2	(zrhlwzceev) = wtuyklvxtt rrjfifvuyx (fffwriozmj )	Negative	01 Jun 2005
ASCO2005	Phase 2/3	Hepatocellular Carcinoma	339	DOX 60 mg/m2	(zrhlwzceev) = msbhuhdomb rrjfifvuyx (fffwriozmj )	Negative	01 Jun 2005